CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

UBS Downgrades MapLight Therapeutics to Neutral From Buy, Adjusts PT to $13 From $52

Negative
AI Analysis

Summary

UBS downgraded MapLight Therapeutics from Buy to Neutral and reduced its price target from $52 to $13, signaling reduced confidence in the company's near-term prospects.

Importance:4/10
Sentiment:
-0.80
analyst_downgradeprice_target_reductionrating_change
Related Companies

Read the original article

Published by yahoo_finance on August 10, 2026 11:43 AM

Read Original